Press "Enter" to skip to content

North America Lung Cancer Therapeutics Market with Key Drivers, Industry Research, Regional Forecast, Top Players, Key Companies and Segment

The study includes an analysis of market growth drivers, opportunities, challenges, restraints, trends, key strategies, market share, geographical analysis, and many more. Also, the study has focused on market size for various segments that are part of the industry. Analyzing the market on the basis of the competitive landscape provides a correct and real-time picture of the market matrix. The growth rate of the industry in coming years play an important role for investors, manufacturers, and stockholders to decide, whether it is the right time to invest in a particular market or not, this study also has focused on the growth rate of the market during the forecast period. For more info click here @ https://www.reportocean.com/industry-verticals/details?report_id=41358

Short Description

By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2026

Market Definition

In lung cancer, cell overgrowth occurs in the lungs and this will lead to less supply of oxygen in the blood stream. Lung cancer causes roughly around 1.6 million deaths each year (more deaths than colon, breast, prostate cancer combined). The lung cancer can be diagnosed by imaging tests, sputum cytology, tissue sample (biopsy). Lung cancer is generally of two types such as small cell lung cancer and non-small cell lung cancer. The non-small cell lung cancer accounts for almost 85% of the total lung cancer. Various treatment facilities are available for the treatment of lung cancer like immunotherapy, chemotherapy, radiation therapy, surgery.

Market Segmentation

> On the basis of cancer type, the market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumors, pulmonary neuroendocrine tumors, mediastinal tumors. The non-small cell lung cancer is further segmented into squamous cell carcinoma, pulmonary adenocarcinoma, adenosquamous carcinoma (ASC), large cell carcinoma, sarcomatoid carcinoma, undifferentiated non-small cell lung cancer, salivary gland-type lung carcinoma. The chest wall tumors segment is further sub divided into primary tumors, metastatic tumors, sarcomas. The pulmonary neuroendocrine tumors are further segmented into carcinoid tumors, large cell neuroendocrine lungs carcinoma and small-cell lung cancer. The mediastinal tumors are further segmented into germ cell tumors, lymphomas, thymomas. The salivary gland-type lung carcinoma sub-segment is further divided into adenoid cystic carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma, epithelial-myoepithelial carcinoma, granular cell lung tumours. The carcinoid tumors sub-segment is further divided into typical carcinoid tumors, atypical carcinoid tumors. The small-cell lung cancer sub-segment is further divided into small cell carcinoma, combined small cell carcinoma.

> On the basis of molecule type, the market is segmented into small molecules, biologics.

> On the drug class, the market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors, others.

> On the basis of treatment type, the market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs. The radiation therapy segment is further divided into external beam, brachytherapy (internal or implant radiation therapy), systemic, stereotactic body radiation therapy (SBRT) / stereotactic ablative radiotherapy (SABR), stereotactic radiosurgery (SRS). The chemotherapy segment is further divided into cisplatin, paclitaxel (taxol), docetaxel (taxotere), gemcitabine (gemzar), alimta, vinorelbine (navelbine), durvalumab (imfinzi) and others. The targeted therapy segment is further divided into epidermal growth factor receptor (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, anti-angiogenesis therapy, monoclonal antibodies, others. The immunotherapy segment is further divided into atezolizumab (tecentriq), durvalumab (imfinzi), nivolumab (opdivo), pembrolizumab (keytruda), others.

> On the basis of therapy type, the market is segmented into single drug therapy, combination therapy.

> On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare, others.

> On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online and others.

Market Players

Some of the prominent players operating in this market are:

> Takeda Pharmaceutical Company Limited

> ONO PHARMACEUTICAL CO., LTD.

> F. Hoffmann-La Roche Ltd

> Novartis AG

> Eli Lilly and Company.

> AstraZeneca

> Boehringer Ingelheim International GmbH

> Merck & Co., Inc.

> CELGENE CORPORATION

> AMGEN INC.

> Sanofi

> Johnson & Johnson Services, Inc.

> Pfizer Inc.

> Sun Pharmaceutical Industries Ltd.

> Dr. Reddy’s Laboratories Ltd.

> ALLERGAN

> Teva Pharmaceutical Industries Ltd.

> Bristol-Myers Squibb Company

> GlaxoSmithKline plc.

> Astellas Pharma Inc.

> Sumitomo Dainippon Pharma Co., Ltd

> Others

Continue…

View Full Report Detail and Table of Content at https://www.reportocean.com/industry-verticals/details?report_id=41358

Request Free Sample Report at https://www.reportocean.com/industry-verticals/sample-request?report_id=41358

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 RESEARCH METHODOLOGY

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 DBMR MARKET POSITION GRID

2.8 DBMR MARKET CHALLENGE MATRIX

2.9 DBMR VENDOR SHARE ANALYSIS

2.10 MULTIVARIATE MODELLING

2.11 PRODUCT TIME LINE

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING CASES OF LUNG CANCER

3.1.2 GROWING NUMBER OF SMOKERS

3.1.3 GOVERNMENT/ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS

3.1.4 INCREASING AWARENESS

3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES

3.2 RESTRAINS

3.2.1 PRICING PRESSURE

3.2.2 HIGH COST

3.3 OPPORTUNITIES

3.3.1 APPROVALS AND PRODUCT PIPEPLINE

3.3.2 HEALTH TOURISM

3.3.3 NEW PRODUCT LAUNCHES

?

3.4 CHALLENGES

3.4.1 SIDE EFFECTS

3.4.2 LACK OF NUMBER OF ONCOLOGISTS

3.4.3 UNMET MEDICAL NEEDS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY OF LUNG CANCER

7 REGULATORY PROCEDURE

8 PIPELINE DRUGS

9 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE

9.1 OVERVIEW

9.2 NON-SMALL CELL LUNG CANCER

9.2.1 SQUAMOUS CELL CARCINOMA

9.2.2 PULMONARY ADENOCARCINOMA

9.2.3 ADENOSQUAMOUS CARCINOMA (ASC)

9.2.4 LARGE CELL CARCINOMA

9.2.5 SARCOMATOID CARCINOMA

9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER

9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA

9.2.7.1 ADENOID CYSTIC CARCINOMA

9.2.7.2 MUCOEPIDERMOID CARCINOMA

9.2.7.3 ACINIC CELL CARCINOMA

9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA

9.2.7.5 GRANULAR CELL LUNG TUMORS

9.3 METASTATIC LUNG CANCER

9.4 MESOTHELIOMA

9.5 CHEST WALL TUMORS

9.5.1 PRIMARY TUMORS

9.5.2 METASTATIC TUMORS

9.5.3 SARCOMAS

9.6 PULMONARY NEUROENDOCRINE TUMORS

9.6.1 CARCINOID TUMORS

9.6.1.1 TYPICAL CARCINOID TUMORS

9.6.1.2 ATYPICAL CARCINOID TUMORS

9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA

?

9.6.3 SMALL-CELL LUNG CANCER

9.6.3.1 SMALL CELL CARCINOMA

9.6.3.2 COMBINED SMALL CELL CARCINOMA

9.7 MEDIASTINAL TUMORS

9.7.1 GERM CELL TUMORS

9.7.2 LYMPHOMAS

9.7.3 THYMOMAS

10 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE

10.1 OVERVIEW

10.2 SMALL MOLECULE

10.3 BILOGICS

11 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS

11.1 OVERVIEW

11.2 ALKYLATING AGENTS

11.3 ANTIMETABOLITES

11.4 MITOTIC INHIBITORS

11.5 MULTIKINASE INHIBITORS

11.6 EGFR INHIBITORS

11.7 OTHERS

12 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE

12.1 OVERVIEW

12.2 RADIATION THERAPY

12.2.1 EXTERNAL BEAM

12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY)

12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)

12.2.4 STEREOTACTIC RADIOSURGERY (SRS)

12.3 CHEMOTHERAPY

12.3.1 CISPLATIN

12.3.2 PACLITAXEL (TAXOL)

12.3.3 VINORELBINE (NAVELBINE)

12.3.4 DOCETAXEL (TAXOTERE)

12.3.5 ALIMTA

12.3.6 GEMCITABINE (GEMZAR)

12.3.7 DURVALUMAB (IMFINZI)

12.3.8 OTHERS

?

12.4 TARGETED THERAPY

12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS

12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS

12.4.3 ANTI-ANGIOGENESIS THERAPY

12.4.4 MONOCLONAL ANTIBODIES

12.4.5 OTHERS

12.5 IMMUNOTHERAPY

12.5.1 ATEZOLIZUMAB (TECENTRIQ)

12.5.2 DURVALUMAB (IMFINZI)

12.5.3 NIVOLUMAB (OPDIVO)

12.5.4 PEMBROLIZUMAB (KEYTRUDA)

12.6 OTHERS

13 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE

13.1 OVERVIEW

13.2 SINGLE DRUG THERAPY

13.3 COMBINATION THERAPY

14 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 HOMECARE

14.5 OTHERS

15 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 HOSPITAL PHARMACY

15.3 RETAIL PHARMACY

15.4 ONLINE

15.5 OTHERS

16 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 CANADA

16.1.3 MEXICO

?

17 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 COMPANY PROFILES

18.1 F. HOFFMANN-LA ROCHE LTD

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 GEOGRAPHICAL PRESENCE

18.1.4 COMPANY SHARE ANALYSIS

18.1.5 PRODUCT PORTFOLIO

18.1.6 RECENT DEVELOPMENTS

18.2 MERCK & CO., INC.

18.2.1 COMPANY OVERVIEW

18.2.2 REVENUE ANALYSIS

18.2.3 GEOGRAPHICAL PRESENCE

18.2.4 COMPANY SHARE ANALYSIS

18.2.5 PRODUCT PORTFOLIO

18.2.6 RECENT DEVELOPMENTS

18.3 BRISTOL-MYERS SQUIBB COMPANY

18.3.1 COMPANY OVERVIEW

18.3.2 REVENUE ANALYSIS

18.3.3 GEOGRAPHICAL PRESENCE

18.3.4 COMPANY SHARE ANALYSIS

18.3.5 PRODUCT PORTFOLIO

18.3.6 RECENT DEVELOPMENTS

18.4 ASTRAZENECA

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 GEOGRAPHICAL PRESENCE

18.4.4 COMPANY SHARE ANALYSIS

18.4.5 PRODUCT PORTFOLIO

18.4.6 RECENT DEVELOPMENTS

18.5 ELI LILLY AND COMPANY

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 GEOGRAPHICAL PRESENCE

18.5.4 COMPANY SHARE ANALYSIS

18.5.5 PRODUCT PORTFOLIO

18.5.6 RECENT DEVELOPMENTS

18.6 ALLERGAN

18.6.1 COMPANY OVERVIEW

18.6.2 REVENUE ANALYSIS

18.6.3 GEOGRAPHICAL PRESENCE

18.6.4 PRODUCT PORTFOLIO

18.6.5 RECENT DEVELOPMENTS

18.7 AMGEN INC.

18.7.1 COMPANY OVERVIEW

18.7.2 REVENUE ANALYSIS

18.7.3 GEOGRAPHICAL PRESENCE

18.7.4 PRODUCT PORTFOLIO

18.7.5 RECENT DEVELOPMENTS

18.8 ASTELLAS PHARMA INC.

18.8.1 COMPANY OVERVIEW

18.8.2 REVENUE ANALYSIS

18.8.3 GEOGRAPHICAL PRESENCE

18.8.4 PRODUCT PORTFOLIO

18.8.5 RECENT DEVELOPMENTS

18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

18.9.1 COMPANY OVERVIEW

18.9.2 REVENUE ANALYSIS

18.9.3 GEOGRAPHICAL PRESENCE

18.9.4 PRODUCT PORTFOLIO

18.9.5 RECENT DEVELOPMENTS

18.10 CELGENE CORPORATION

18.10.1 COMPANY OVERVIEW

18.10.2 REVENUE ANALYSIS

18.10.3 GEOGRAPHICAL PRESENCE

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPMENTS

18.11 DR. REDDY’S LABORATORIES LTD.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 GEOGRAPHICAL PRESENCE

18.11.4 PRODUCT PORTFOLIO

18.11.5 RECENT DEVELOPMENTS

?

18.12 GLAXOSMITHKLINE PLC.

18.12.1 COMPANY OVERVIEW

18.12.2 REVENUE ANALYSIS

18.12.3 GEOGRAPHICAL PRESENCE

18.12.4 PRODUCT PORTFOLIO

18.12.5 RECENT DEVELOPMENTS

18.13 JOHNSON & JOHNSON SERVICES, INC.

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 GEOGRAPHICAL PRESENCE

18.13.4 PRODUCT PORTFOLIO

18.13.5 RECENT DEVELOPMENTS

18.14 NOVARTIS AG

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 GEOGRAPHICAL PRESENCE

18.14.4 PRODUCT PORTFOLIO

18.14.5 RECENT DEVELOPMENT

18.15 ONO PHARMACEUTICAL CO., LTD.

18.15.1 COMPANY OVERVIEW

18.15.2 REVENUE ANALYSIS

18.15.3 GEOGRAPHICAL PRESENCE

18.15.4 PRODUCT PORTFOLIO

18.15.5 RECENT DEVELOPMENTS

18.16 PFIZER INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 RECENT FINANCIALS

18.16.3 GEOGRAPHICAL PRESENCE

18.16.4 PRODUCT PORTFOLIO

18.16.5 RECENT DEVELOPMENTS

18.17 SANOFI

18.17.1 COMPANY OVERVIEW

18.17.2 REVENUE ANALYSIS

18.17.3 GEOGRAPHICAL PRESENCE

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENTS

?

18.18 SUMITOMO DAINIPPON PHARMA CO., LTD.

18.18.1 COMPANY OVERVIEW

18.18.2 REVENUE ANALYSIS

18.18.3 GEOGRAPHICAL PRESENCE

18.18.4 PRODUCT PORTFOLIO

18.18.5 RECENT DEVELOPMENTS

18.19 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 GEOGRAPHICAL PRESENCE

18.19.4 PRODUCT PORTFOLIO

18.19.5 RECENT DEVELOPMENTS

18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED

18.20.1 COMPANY OVERVIEW

18.20.2 REVENUE ANALYSIS

18.20.3 GEOGRAPHICAL PRESENCE

18.20.4 PRODUCT PORTFOLIO

18.20.5 RECENT DEVELOPMENTS

18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.21.1 COMPANY OVERVIEW

18.21.2 REVENUE ANALYSIS

18.21.3 GEOGRAPHICAL PRESENCE

18.21.4 PRODUCT PORTFOLIO

18.21.5 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

?

Request Free Sample Report at https://www.reportocean.com/industry-verticals/sample-request?report_id=41358

Note: The report historic years and forecast period can be customized on the request. Moreover, the scope of a published report can be modified as per the requirement, specific geography or ‘country-based’ analysis can be provided as a part of customization

Follow us on:

Facebook:          https://www.facebook.com/reportocean

Twitter:              https://twitter.com/reportocean

LinkedIn:            https://in.linkedin.com/company/reportocean

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)
Contact Person: Sandeep Singh
Email: sales@reportocean.com

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *